The global Qianlie Antong Capsules market size is predicted to grow from US$ 11 million in 2025 to US$ 14.1 million in 2031; it is expected to grow at a CAGR of 4.2% from 2025 to 2031.

Qianlie Antong Capsule is a Chinese patent medicine formulated according to traditional Chinese medicine theory, mainly used to treat benign prostatic hyperplasia (BPH) and its symptoms such as frequent urination, urgency, increased nocturia, and dysuria. The drug combines a variety of natural herbal ingredients that have the effects of promoting blood circulation and removing blood stasis, clearing away heat and dampness, and softening and dispersing nodules, such as Danshen, Red Peony Root, and Alisma Orientalis, etc. It achieves the purpose of treatment by improving local blood circulation in the prostate, reducing inflammatory reactions, and relieving spasms of the bladder neck and urethral smooth muscles.

United States market for Qianlie Antong Capsules is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Qianlie Antong Capsules is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Qianlie Antong Capsules is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Qianlie Antong Capsules players cover Inner Mongolia Tianqi Sino-Mongolian Pharmaceutical Co., Ltd., Inner Mongolia Huifeng Pharmaceutical Co., Ltd., Jiangxi Deshang Pharmaceutical Co., Ltd., Chengde Yanfeng Pharmaceutical Co., Ltd., Jiangsu Kangyuan Pharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Qianlie Antong Capsules Industry Forecast” looks at past sales and reviews total world Qianlie Antong Capsules sales in 2024, providing a comprehensive analysis by region and market sector of projected Qianlie Antong Capsules sales for 2025 through 2031. With Qianlie Antong Capsules sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Qianlie Antong Capsules industry.

This Insight Report provides a comprehensive analysis of the global Qianlie Antong Capsules landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Qianlie Antong Capsules portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Qianlie Antong Capsules market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Qianlie Antong Capsules and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Qianlie Antong Capsules.

This report presents a comprehensive overview, market shares, and growth opportunities of Qianlie Antong Capsules market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Bottled
    Boxed

Segmentation by Application:

    Hospital
    Clinic
    Other

This report also splits the market by region:

    Americas

        United States
        Canada
        Mexico
        Brazil

    APAC

        China
        Japan
        Korea
        Southeast Asia
        India
        Australia

    Europe

        Germany
        France
        UK
        Italy
        Russia

    Middle East & Africa

        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

    Inner Mongolia Tianqi Sino-Mongolian Pharmaceutical Co., Ltd.
    Inner Mongolia Huifeng Pharmaceutical Co., Ltd.
    Jiangxi Deshang Pharmaceutical Co., Ltd.
    Chengde Yanfeng Pharmaceutical Co., Ltd.
    Jiangsu Kangyuan Pharmaceutical Co., Ltd.
    Liaoning Deshan Pharmaceutical Co., Ltd.
    Guizhou Yibai Women's Pharmaceutical Co., Ltd.
    Shaanxi Huaxi Pharmaceutical Co., Ltd.
    Huludao Guodi Pharmaceutical Co., Ltd.
    Shandong Huaxin Pharmaceutical Group Co., Ltd.
    Shaanxi Junbisa Pharmaceutical Co., Ltd.
    Hunan Warner Pharmaceutical Co., Ltd.
    Xi'an Renren Pharmaceutical Co., Ltd.
    Heilongjiang Jiren Pharmaceutical Co., Ltd.
    Hongyun Pharmaceutical (Lianghe) Co., Ltd.
    Guangxi Ditai Pharmaceutical Co., Ltd.
    Shandong Hualu Pharmaceutical Co., Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Qianlie Antong Capsules market?
What factors are driving Qianlie Antong Capsules market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Qianlie Antong Capsules market opportunities vary by end market size?
How does Qianlie Antong Capsules break out by Type, by Application?